Edward Scolnick is a core investigator at the Broad Institute, the former founding director of the Stanley Center for Psychiatric Research at Broad Institute, and former head of research and development at Merck Research Laboratories.
Education and early career[edit]
Scolnick earned a BA in 1961 from Harvard University and an MD in 1965 from Harvard Medical School.[1] After medical school, he joined the Public Health Service to avoid being drafted into the Vietnam War.[2] During his 15 years at the NIH's National Cancer Institute, Scolnick discovered the RAS oncogene that is involved in the critical signaling pathway that shifts an otherwise normal cell into the aggressive cells known as tumor cells. His work helped establish the concept of blocking signaling pathways as fundamental to cancer biology and drug discovery.[citation needed]
Scolnick joined Merck in 1982 as executive director of virus and cell biology, after being recruited from the National Institutes of Health. He was head of Research at Merck Research Laboratories from 1985 until he stepped down in 2002.[3] While at Merck, he was involved in the development and introduction of 29 new medications and vaccines.[4]
He was a key figure in the development and marketing of Vioxx, which was pulled from the market after it was discovered that the drug caused a dangerously high risk of myocardial infarction.[4] Legal claims resulting from this has cost Merck billions. During the 5 years it was available in the US, more than 38,000 deaths were related to Vioxx use, and up to 25 million Americans had taken the drug.[5] In the subsequent investigations, it was revealed that it was likely that Merck knew about the adverse effects of the drug, and Scolnick had dismissed them in order to push the drug to market before Bayer's Celebrex.[6][7]
Later career[edit]
Scolnick began as the founding director of the Stanley Center for Psychiatric Research at Broad Institute in 2007. In early 2012, Scolnick stepped down as director and became the Stanley Center’s chief scientist, being succeeded by Steven Hyman.
He is an elected member of the National Academy of Sciences and its Institute of Medicine, and the American Academy of Arts and Sciences. He was also appointed to the Board of Visitors at the University of Pittsburgh School of Medicine. MIT awards the "Edward M. Scolnick Prize in Neuroscience" in his honor.[8]
References[edit]
- Jump up ^ "Boston and San Francisco based Health Care and Life Science Investment Firm - Clarus". www.clarusfunds.com.
- Jump up ^ "NCI Oral History Project, Interview with Edward Scolnick, M.D" (PDF). history.nih.gov. June 24, 1998. Retrieved 2017-05-19.
- Jump up ^ "Edward M. Scolnick, M.D., Steps Down as President of Merck Research Laboratories and Member of Board of Directors, Returns to Laboratories - Evaluate". www.evaluategroup.com.
- ^ Jump up to: a b "Will Merck Survive Vioxx? - November 1, 2004". archive.fortune.com.
- Jump up ^ "Vioxx - Uses, Side Effects, History and Market Withdrawal".
- Jump up ^ "Merck's Fall from Grace - The Scientist Magazine®". The Scientist.
- Jump up ^ Bowe, Christopher (20 June 2005). "Scolnick: retired but far from retiring" – via Financial Times.
- Jump up ^ "Edward M. Scolnick Prize in Neuroscience - McGovern Institute for Brain Research at MIT". mcgovern.mit.edu.
Nina Scolnik
B. Mus, Oberlin Conservatory; Diploma, Juilliard School.
Pianist Nina Scolnik has concertized in the United States and abroad as a recitalist, soloist with orchestra, chamber musician and collaborative pianist.
She has been a guest artist with the American, Angeles, Lydian, and Blaeu String Quartets and has collaborated with international cellists Nathaniel Rosen, Gerhard Mantel and Vagram Saradjian. Recent European venues include performances at the Rudolfinum in Prague with principals of the Royal Concertgebouw Orchestra of Amsterdam and the Palais Auersperg in Vienna as a soloist with the Wiener Residenzorchester. Scolnik has performed and taught at celebrated music festivals in Europe and in the United States including the Schlern International Music Festival in Voels am Schlern, Italy, the Ameropa International Chamber Music Festival in Prague, Czech Republic, Pianofest Austria in Bad Aussee, Austria, the Williams International Piano Festival, Tulane University Keyboard Festival, and the Amherst, New World, and Aspen Music Festivals.
Widely recognized for her master classes, lectures, and work with injured pianists, Ms. Scolnik has presented at music conferences, universities, and festivals in the United States, Canada, and Europe. She served as a faculty member of the Taubman Institute of Piano from 1979 to 2002, and at the Golandsky International Piano Institute at Princeton University in 2004. She currently serves on the piano faculty and as Associate Chair for Performance at the University of California, Irvine, where she has groomed pianists for serious careers as performers and teachers for over 25 years.
Born in Lewiston, Maine, Ms. Scolnik is a graduate of both the Oberlin Conservatory and the Juilliard School of Music. Her teachers have included Edna Golandsky, Dorothy Taubman, Artur Balsam, Joseph Schwartz, Martin Canin, Lenore Engdahl, and Natasha Chances.
Title:
Senior Lecturer with Security of Employment
